CompletedPhase 2NCT03799510
Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children
Studying Schistosomiasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Oswaldo Cruz Foundation
- Principal Investigator
- Miriam Tendler, MD, PhDOswaldo Cruz Foundation
- Intervention
- Sm14(biological)
- Enrollment
- 95 enrolled
- Eligibility
- 8-11 years · All sexes
- Timeline
- 2018 – 2019
Study locations (1)
- Biomedical Research Center EPLS, Saint-Louis, Senegal
Collaborators
Orygen Biotecnologia SA · Biomedical Research Center EPLS · Access to Advanced Health Institute (AAHI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03799510 on ClinicalTrials.govOther trials for Schistosomiasis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06698510Introduction of Arpraziquantel Treatment for Schistosomiasis Control in Preschool-aged Children in Endemic Areas: A Small-scale Public Health Intervention StudyPeter Steinmann
- RECRUITINGNANCT06873308Assessment of Infection Activity in Travelers and Migrants Diagnosed With Chronic SchistosomiasisIRCCS Sacro Cuore Don Calabria di Negrar